#Germany #Frankfurt #Implantica #RefluxStop™ #GERD

Implantica's Groundbreaking Research on RefluxStop™

Implantica AG, a leading MedTech company dedicated to innovating technologies for body integration, has recently released significant research insights from Germany emphasizing the impressive results achieved with their RefluxStop™ device, which is designed to treat acid reflux, a condition affecting around one billion individuals worldwide. Published in the respected Journal of Laparoendoscopic Advanced Surgical Techniques, this study reflects the results observed in real-world scenarios, parallel to those recorded during clinical trials that led to the device's CE mark approval.

The study titled "Experience with an innovative surgical treatment option for gastroesophageal reflux disease: Results of 28 patients in a retrospective analysis," was spearheaded by Dr. Moustafa Elshafei, a prominent anti-reflux surgeon and Chief of General and Visceral Surgery at St. Elisabethen Hospital in Frankfurt, Germany. In his evaluation, Dr. Elshafei highlighted the remarkable difference this device brings to the treatment of gastroesophageal reflux disease (GERD).

According to Dr. Elshafei, who possesses extensive experience treating reflux patients and participating in technological advancements over the years, the RefluxStop™ approach is transformative. Unlike traditional methods that compress the food passageway, the RefluxStop™ device effectively restores the body's natural anatomy and physiology, including the sphincter muscle. This shift away from invasive measures results in excellent patient outcomes without the common complications associated with conventional surgeries.

Elshafei expressed his enthusiasm, stating, "All instances of preoperative heartburn, regurgitation, and dysphagia observed in our study were completely resolved using RefluxStop™, which reflects high patient satisfaction and compelling results. This procedure fills a significant gap in surgical approaches, offering a comprehensive solution for GERD patients."

Dr. Peter Forsell, Founder and CEO of Implantica, praised the study's findings and Dr. Elshafei's involvement, emphasizing the urgency for reliable surgical interventions for GERD, particularly in Germany, where the economic burden of the disease is substantial—estimated at €688 million annually due to reduced productivity.

Furthermore, Dr. Forsell remarked, “The RefluxStop™ procedure has shown itself to be not only safe but also a reliable alternative that could redefine surgical treatments for GERD. We are excited to witness the positive impact this innovative device will bring to patients and healthcare providers alike.”

As an industry pioneer, Implantica aims to reshape anti-reflux treatments, with their lead product RefluxStop™ set to revolutionize surgical interventions. This technology diverges from traditional surgical solutions that often lead to complications such as swallowing difficulties, thereby addressing the root cause of acid reflux without undue pressure on anatomical structures.

The study reaffirmed that the RefluxStop™ device successfully restores the anti-reflux barrier by reconstructing its components, thus allowing the body to rectify acid reflux issues autonomously. The RefluxStop™ device not only signifies a major advancement in Reflux treatment but also highlights Implantica's commitment to integrating advanced technology for better patient outcomes in the medical field.

As we move forward, it will be fascinating to see how RefluxStop™ continues to perform and possibly evolve the current surgical landscape for GERD treatment, making life significantly better for millions of people living with this challenging condition. For more information about Implantica and its innovative products like RefluxStop™, please visit their website at www.implantica.com.